Pharma major Novartis plummets 10%, heading for worst day on record after three drug trial setbacks
Shares of Novartis tanked on Tuesday after results from its del-desiran drug trial disappointed investors.
Sourcing & attribution. Newseze provides AI-curated summaries, narrative framing, and editorial analysis. The underlying reporting was contributed by CNBC Top News; tap “Open original source” above to read their full reporting and support the contributing newsroom directly.
Newseze's algorithm reads the story and answers your question — calmly, factually, with source attribution. No comments, no flame wars — just answers.
No questions yet. Be the first.
Answers reflect Newseze's editorial framework applied under fair use (17 U.S.C. § 107). Not financial, legal, medical, or tax advice. Hate speech and racial slurs are blocked.
Related stories
Why it mattersTreasury yields moved higher as investors look ahead to more key economic data releases this week.
By Michael·1h ago
Why it mattersA Greenville, North Carolina, police officer speaks to an apartment resident, as seen on her Ring video doorbell.
By Michael·1h ago
Why it mattersMore than 60% of cryptocurrency platforms that lost money due to cyberattacks had undergone independent security audits, CoinGecko said.
By Michael·1h ago
Why it mattersEighteen maritime bodies warned Tuesday that geopolitical tensions and a growing shadow fleet threaten to undermine international shipping and weaken trade.
By Michael·1h ago